PTOISB08x (08-03)
Approved for use through 07/31/2006 OM5 0651-0301
U.S. Petient and Trademark Office; U.S. DEPARTMENT OF COMMERCE,
and to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE	Application Number		10551101
	Filing Date		2005-09-26
	First Named Inventor Muell		eller
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3732
(Not for Submission and or or it has)	Examiner Name		
	Attorney Docket Number		ZP192-05009

	Remove					
Examiner Initial*			Kind Code ¹	Issue Date Name of Patentee of Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6875211	B2	2005-04-05	Nichols et al.	
	2	6752807	B2	2004-06-22	Lin et al.	
	3	6786903	B2	2004-09-07	Lin	
	4	6709435	B2	2004-03-23	Lin	
	5	6869973	B2	2005-03-22	Garvey et al.	
	6	RE37161		2001-05-01	Michelson et al.	
	7	6595992	В1	2003-07-22	Wagner et al.	
	8	6102948		2000-08-15	Brosnahan, III	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10551101		
	Filing Date		2005-09-26		
	First Named Inventor	Muel	er		
	Art Unit		3732		
	Examiner Name				
Attorney Docket Number		er	ZP192-05009		

	9	5380323		1995-01-10	Howland	
If you wisi	h to ac	dd additional U.S. Paten			lease click the Add button. CATION PUBLICATIONS	Add Remove
Examiner Initial*	Cite No	Publication Number	ication Number Kind Code ¹ Date Name of Patentee or Applicant of cited Document			
	1	20050055026	A1	2005-03-10	Biedermann et al.	
	2	20020120272	A1	2002-08-29	Yuan et al.	
	3	20040116929	A1	2004-06-17	Barker et al.	
	4	20040267264	A1	2004-12-30	Konieczynski et al.	
	5	20050070899	A1	2005-03-31	Doubler et al.	
	6	20050119658	A1	2005-06-02	Ralph et al.	
	7	20050137594	A1	2005-06-23	Doubler et al.	
	8	20050154389	A1	2005-07-14	Selover et al.	

	Application Number		10551101	
	Filing Date		2005-09-26	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Mueli		ler	
(Not for submission under 37 CFR 1.99)	Art Unit		3732	
(Examiner Name			
	Attorney Docket Numb	er	ZP192-05009	

9	20050177154	A1	2005-08-11	Moumene et al.	
10	20050187555	A1	2005-08-25	Biedermann et al.	
11	20050192571	A1	2005-09-01	Abdelgany	
12	20050192573	A1	2005-09-01	Abdelgany et al.	
13	20050192589	A1	2005-09-01	Raymond et al.	
14	20050228382	A1	2005-10-13	Richelsoph et al.	
15	20050251139	A1	2005-11-10	Roh	
16	20050256525	A1	2005-11-17	Culbert et al.	
17	20050277923	A1	2005-12-15	Sweeney	
18	20050283157	A1	2005-12-22	Coates et al.	
19	20050288671	A1	2005-12-29	Yuan et al.	

	20	20060036252	A1	2006-0	2-16	Baynham et a	l.				
	21	20060036260	A1	2006-0	2-16	Runco et al.					
	22	20060052783	A1	2006-0	3-09	Dant et al.					
	23	20060052784	A1	2006-0	3-09	Dant et al.					
	24	20060058788	A1	2006-03-16		Hammer et al.					
	25	20060074419	A1	2006-0	4-06	Taylor et al.					
If you wis	h to a	dd additional U.S. Publi						d butto			
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³		Country Kind Code ² i Code ⁴		Publication Date	Name of Patente Applicant of cited Document		where Re	or Relevant	T4
	1	1089911	EΡ		B1	2004-05-26	Nichols				
	2	1297792	EP		A2	2003-04-02	Nichols				
	3	1323390	EP		A1	2003-07-02	Lin				

Application Number 10551101 Filing Date 2005-09-26 INFORMATION DISCLOSURE First Named Inventor Mueller STATEMENT BY APPLICANT Art I Init 3732 (Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number ZP192-05009

	4	2732887	FR		1996-10-18	Gau				
	5	2736535	FR		1997-01-17	Martin				
	6	0578320	EP	B1	2001-09-26	Allard et al.				
	7	0778007	EP	A1	1997-06-11	Pfaifer				
	8	0443892	EP	B1	1991-08-28	Cotrel				
	9	0242708	EP	B1	1992-11-19	Harms et al.				
If you wisi	h to a	dd additional Foreign P				ease click the Add buttor				
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove			
Examiner linitials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposism, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								Τs		
	1									
If you wis	from wish to add additional non-patent literature document citation information please click the Add button Add									

EXAMINER SIGNATURE

Date Considered Examiner Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application Number		10551101	
INFORMATION DIGGI COURT	Filing Date		2005-09-26	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Muel		ler	
(Not for submission under 37 CFR 1.99)	Art Unit		3732	
(Examiner Name			
	Attorney Docket Numb	er	ZP192-05009	

See four Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. * Exister office in all assets for electrons, by the loss letter code (WPO) Standard 51.3. * *Projectioned person persons are supported by searly for heavy persons. * Projectioned persons are supported by searly for heavy persons. * Projectioned persons are supported by searly for the persons are supported symbols as indicated on the document by the appropriate symbols as indicated on the document under WPO Standard 51.16 if possible. * Applicant is to place a check mark here if English targular stratations a statistical.**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10551101			
Filing Date		2005-09-26			
First Named Inventor	Muel	Mueller			
Art Unit		3732			
Examiner Name					
Attorney Docket Number		ZP192-05009			

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Robert Eichenberger/	Date (YYYY-MM-DD)	2006-06-08
Name/Print	Robert H. Eichenberger	Registration Number	42509

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$3 U.S. C.2(b)(2); (2) familishing of the information solicided is columbrary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORIE is a to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested required to the process of the process and/or examine your submission related to a patient application or patient. If you do not furnish the requested required to the processing of the patient authorisms, which may result in termination of proceedings or abandorment of the accidation or exemption of the patient and the patient and the processing of the patient and the patient and the processing of the patient and the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 11.4, as a routine use, to the public if the record via 96 flow an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application gone to public insepections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.